85 Results
Paperless labs, AI-ready teams, and 11 years at one company, Dr Rupesh Kelaskar on why staying long, thinking like an analyst, and understanding AI (not fearing it) defines the future of pharma QC.
CAR-T therapies can cure blood cancers. They cost $400k-$500k per patient. Ms. Archana Ganesh on why manufacturing — not science — is the last wall standing.
Dr Rajiv Desai on why India's next pharma milestone isn't cheaper generics, it's medicines the world calls Made in India.
A new parent leading baby care science at scale. Dr. Talluri on why clinical evidence — not marketing — is what consumers actually trust.
Dr Santosh Indraksha topped UPSC, left J&J's global postings, and joined CDSCO. On Schedule M, 295 medicines during COVID-19, QR codes, and why AI must assist regulators but never replace them.
Mehul Shah took 11 years to hit Rs 25 crore in turnover, then waited again before owning his own R&D. On the ₹250 stipend, building Volini, the PACO framework, and why patience beats speed in pharma.
Hemanth Panasa delayed an FDA inspection by 9 months and got zero observations. On aseptic failures, media fills, gowning myths, and why the biggest contamination risk in steriles is always human.